Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander C Schmidt

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Drug Safety|December 30, 2019
Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 SeasonGael Dos Santos, Bach-Yen Nguyen, Silvia Damaso, et al.
NPJ Vaccines|November 1, 2022
Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adultsHeather Friberg, Morgan Gargulak, Amanda Kong, et al.
Plos Neglected Tropical Diseases|October 5, 2018
Dengue illness index-A tool to characterize the subjective dengue illness experienceStephen J Thomas, Liane Agulto, Kim Hendrickx, et al.
The Journal of Infectious Diseases|August 17, 2019
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized TrialTino F Schwarz, Roderick A McPhee, Odile Launay, et al.
Journal of Virology|July 11, 2008
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primatesEmmalene J Bartlett, Ann-Marie Cruz, Janice Esker, et al.
The American Journal of Tropical Medicine and Hygiene|October 29, 2009
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteersPeter F Wright, Anna P Durbin, Stephen S Whitehead, et al.
Virus Research|November 4, 2004
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003Alexander C Schmidt, Teresa R Johnson, Peter J M Openshaw, et al.
Frontiers in Nutrition|May 15, 2026
Impact of <i>Bifidobacterium infantis</i> supplementation on growth, health outcomes, and gut microbiome features in underweight infants from PakistanJanie Parrino, Justine Sunshine, Kenneth Tripp, et al.
The Journal of Infectious Diseases|February 6, 2018
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 TrialsJiri Beran, Jason D Lickliter, Tino F Schwarz, et al.
The American Journal of Tropical Medicine and Hygiene|March 8, 2018
Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto RicoClemente Diaz, Leyi Lin, Luis J Martinez, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Drug Safety|December 30, 2019
Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 SeasonGael Dos Santos, Bach-Yen Nguyen, Silvia Damaso, et al.
NPJ Vaccines|November 1, 2022
Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adultsHeather Friberg, Morgan Gargulak, Amanda Kong, et al.
Plos Neglected Tropical Diseases|October 5, 2018
Dengue illness index-A tool to characterize the subjective dengue illness experienceStephen J Thomas, Liane Agulto, Kim Hendrickx, et al.
The Journal of Infectious Diseases|August 17, 2019
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized TrialTino F Schwarz, Roderick A McPhee, Odile Launay, et al.
Journal of Virology|July 11, 2008
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primatesEmmalene J Bartlett, Ann-Marie Cruz, Janice Esker, et al.
The American Journal of Tropical Medicine and Hygiene|October 29, 2009
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteersPeter F Wright, Anna P Durbin, Stephen S Whitehead, et al.
Virus Research|November 4, 2004
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003Alexander C Schmidt, Teresa R Johnson, Peter J M Openshaw, et al.
Frontiers in Nutrition|May 15, 2026
Impact of <i>Bifidobacterium infantis</i> supplementation on growth, health outcomes, and gut microbiome features in underweight infants from PakistanJanie Parrino, Justine Sunshine, Kenneth Tripp, et al.
The Journal of Infectious Diseases|February 6, 2018
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 TrialsJiri Beran, Jason D Lickliter, Tino F Schwarz, et al.
The American Journal of Tropical Medicine and Hygiene|March 8, 2018
Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto RicoClemente Diaz, Leyi Lin, Luis J Martinez, et al.
Pageof 6